Table 3.

IC₅₀ and standard errors for HNSCC cell lines after treatment with cetuximab for 168h with MK2206 added during the last 72h of treatment.

Cell line	Condition	IC50 MK2206 (µM)	P-value
SC263-S	MK2206	2.067 ± 0.177	–
	MK2206 + 0.5 nM cetuximab	1.253 ± 0.078	0.127
	MK2206 + 1 nM cetuximab	1.200 ± 0.043	0.102
	MK2206 + 5 nM cetuximab	1.002 ± 0.049	0.051
SCC22b-S	MK2206	3.541 ± 0.540	–
	MK2206 + 0.5 nM cetuximab	1.919 ± 0.197	0.112
	MK2206 + 1 nM cetuximab	1.787 ± 0.071	0.082
	MK2206 + 5 nM cetuximab	1.187 ± 0.043	0.027
SC263-R	MK2206	4.372 ± 1.182	–
	MK2206 + 5 nM cetuximab	1.851 ± 0.315	0.045
	MK2206 + 25 nM cetuximab	1.815 ± 0.201	0.054
	MK2206 + 50 nM cetuximab	1.51 ± 0.264	0.090
SCC22b-R	MK2206	1.073 ± 0.038	–
	MK2206 + 5 nM cetuximab	0.710 ± 0.034	0.052
	MK2206 + 25 nM cetuximab	0.769 ± 0.061	0.102
	MK2206 + 50 nM cetuximab	0.670 ± 0.033	0.033

P < 0.050, significant difference in IC₅₀ compared to MK2206 monotherapy. P < 0.050 are indicated in bold. -, cannot be calculated. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.